Allergan's aesthetics products and eye care and other medicines could help AbbVie shore up revenue. David Maris, a research analyst at Wells Fargo who covers Allergan, told CNBC's " Power Lunch " on Tuesday that he isn't convinced that the deal is a better long-term alternative for Allergan shareholders looking past Humira's patent expiration. But in a follow-up phone interview, Maris added that the stock had been underpeforming for so long, the board had to do something. The deal is a "little disappointing," Maris said." "I can see why AbbVie wants to diversify away from Humira.